Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simlukafusp alfa Monotherapy or with Trastuzumab/Cetuximab in Advanced Solid Tumors
NCT02627274Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2015
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 1, open-label trial of simlukafusp alfa in solid tumor, breast cancer and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose-Limiting Toxicities, Maximum Tolerated Dose of RO6874281 and 6 more. Started Dec 2015; status: completed.
02
Drugs
simlukafusp alfa
03
Conditions
solid tumorbreast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02627274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627274.